RESUMEN
Fifty blood donors coming to Sheikh Zayed Hospital, Lahore were assessed to ascertain the prevalence of Anti-HCV and HBsAg in general population. Four% of blood donors were found to be positive for Anti-HCV while 8% were positive for HBsAg. None of them showed simultaneous co-infection with Anti-HCV and HBsAg. Highest percentage of donors [33.33%] was positive in the 41-60 years of age while in the 0-20 range of years of life, maximum% [20%] of donors were positive for HBsAg. The prevalence was significantly high in 0-20 years of life for HBsAg as compared with anti-HCV [20% vs 0%] whereas the prevalence of anti-HCV was significantly high in 41-60 years of life as compared with HBsAg [33.33% vs 0%]. The prevalence was not significantly different in 21-40 years of life. We concluded that HbsAg was alarmingly higher though the rising rate of Anti-HCV was still more striking
Asunto(s)
Humanos , Masculino , Femenino , Hepatitis B/epidemiología , Anticuerpos contra la Hepatitis C , Antígenos de Superficie de la Hepatitis B , Prevalencia , Donantes de Sangre/estadística & datos numéricosRESUMEN
Seventy live patients with history of multiple transfusions were evaluated for the prevalence of anti-HCV and HBsAg in Sheikh Zayed Hospital, Lahore. Ten [13.33%] out of 75 patients were positive for HBsAg while 25[33.33%] out of 75 patients were reactive to anti-HCV. Six out of 75 patients were positive for both agents among our patients. 32.14% of males and 36.84% of females were positive for anti-HCV whereas 10.71% of males and 21.05% of females were positive for anti-HCV and HBsAg respectively
Asunto(s)
Humanos , Masculino , Femenino , Antígenos de Superficie de la Hepatitis B , Antígenos de la Hepatitis C , Transfusión Sanguínea , Vacunas contra Hepatitis ViralRESUMEN
The aim of this study was to find out the prevalence of anti-HCV and HbsAg in haemodialysis patients. Out of 75 haemodialysis patients, 48 [64%] were reactive for anti-HCV, 4 [5.33%] were positive for HBsAg while 2 [2.67%] showed exposure to both agents. Highest prevalence of [75%] of haemodialysis patients was found in the 61-80 years of life for anti-HCV while 65.62%, 60% and 42.30% was the prevalence of anti-HCV in 21-40, 0-20 and 41-60 years of life. The prevalence of HBsAg as compared with anti-HCV was significantly lower in all ranges of years of life